Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP21279 and Sinemet in Parkinson's Disease
NCT00914602Phase 2Completed
- Sponsor
- XenoPort, Inc.
- Start
- May 2009
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XP21279 in Parkinson's disease (PD), sponsored by XenoPort, Inc.. Started May 2009; status: completed.
02
Drugs
XP21279
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00914602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00914602.